--------------------------------------------------------------------------------

                      SECURITIES AND EXCHANGE COMMISSION
                           WASHINGTON, D.C.   20549



                                   FORM 8-K



                                CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 5(D) OF
                      THE SECURITIES EXCHANGE ACT OF 1934



        Date of Report (Date of Earliest Event Reported) July 25, 2001



                     E. I. du Pont de Nemours and Company
            (Exact Name of Registrant as Specified in Its Charter)



         Delaware                        1-815                    51-0014090
(State or Other Jurisdiction          (Commission             (I.R.S. Employer
     of Incorporation)                File Number)           Identification No.)


                              1007 Market Street
                         Wilmington, Delaware   19898
                   (Address of principal executive offices)



     Registrant's telephone number, including area code:   (302) 774-1000

--------------------------------------------------------------------------------

                                       1


Item 5.  Other Events
         ------------

         The Registrant files, pursuant to Regulation FD, its earnings news
release dated July 25, 2001, entitled "DuPont Reports Second Quarter 2001
Earnings," a copy of which is below. This earnings news release is also filed in
connection with Debt and/or Equity Securities that may be offered on a delayed
or continuous basis under Registration Statements on Form S-3 (No. 33-53327,
No.33-61339, No. 33-60069 and No. 333-86363).


July 25, 2001                       Contact:   Clif Webb
WILMINGTON, Del.                               302-774-4005
                                               r-clifton.webb@usa.dupont.com



                  DUPONT REPORTS SECOND QUARTER 2001 EARNINGS
                  -------------------------------------------


Summary
-------
 .    Second quarter 2001 earnings excluding one-time items were $.41 per share,
     54 percent below second quarter 2000 earnings of $.90 per share.

 .    Net income was principally reduced by $270 million from lower volume, $190
     million from higher raw material costs, and a $35 million impact from the
     stronger U.S. dollar.

 .    One-time items in the quarter total a net charge of $.62 per share,
     principally for previously announced employee terminations, facilities
     shutdowns, and asset write-downs.

 .    Segment sales in second quarter 2001 of $7.8 billion decreased 12 percent
     versus second quarter 2000, principally reflecting significantly lower
     volume.

 .    Worldwide local currency selling prices were up 1 percent. Adverse currency
     effects, principally from the weaker euro and Japanese yen, reduced second
     quarter worldwide segment sales by 2 percent.

 .    On June 7, 2001, the company announced an agreement to sell DuPont
     Pharmaceuticals to Bristol-Myers Squibb Company for $7.8 billion. On July
     12, 2001, the company completed the previously announced sale of selected
     U.S. polyester businesses to Alpek S.A. de C.V.


                             Earnings  Comparisons
                             ---------------------
                             ($ per share diluted)

                    --------------------------------------------
                                               2Q'01       2Q'00
                    --------------------------------------------
                    Underlying                 .41         .90
                    --------------------------------------------
                    One-Time Items            (.62)       (.25)
                    --------------------------------------------
                    Reported                  (.21)        .65
                    --------------------------------------------

                                       2


     "Industries important to many of our customers -- electronics, automotive,
textiles and chemicals -- have been particularly affected by the economic
downturn.  This has temporarily reduced fundamental demand for our products,"
said Charles O. Holliday, Jr., DuPont chairman and chief executive officer.  "In
response to lower levels of business activity, we have taken actions to reduce
costs and enrich product mix, and as a result, we expect significant earnings
leverage when demand improves."

Global Sales and Income
------------------------

     For the quarter, consolidated sales totaled $7.0 billion compared to $7.9
billion in 2000.  Segment sales, including transfers and a pro rata share of
sales by equity affiliates, were $7.8 billion, down 12 percent from $8.8 billion
in 2000.  Net income before one-time items was $432 million versus $949 million
in 2000.  The earnings decline reflects significantly lower results across all
the company's segments principally due to lower U.S. sales volumes, higher raw
material costs, and a stronger U.S. dollar.

     Net income including one-time items was a loss of $213 million, compared to
earnings of $688 million in the second quarter of 2000.
One-Time Items
--------------

     One-time items are described in the notes to the accompanying financial
statements and are summarized in the table below:



----------------------------------------------------------------------------------------------------------------------------
                                                         $MM Pretax               $MM After-Tax            ($ Per Share)
----------------------------------------------------------------------------------------------------------------------------
                                                                                                 
                                                         2001         2000         2001         2000        2001        2000
----------------------------------------------------------------------------------------------------------------------------
Pioneer - Purchase Accounting                                         (220)                     (138)                   (.13)
----------------------------------------------------------------------------------------------------------------------------
Sale of Affiliate Stock                                    52                        34                      .03
----------------------------------------------------------------------------------------------------------------------------
Benlate(R) Accrual                                                    (100)                      (62)                   (.06)
----------------------------------------------------------------------------------------------------------------------------
Employee Separations/Facility Shutdowns                  (743)         (98)        (491)         (61)       (.47)       (.06)
----------------------------------------------------------------------------------------------------------------------------
Asset Impairments (Principally Polyester)                (303)                     (188)                    (.18)
----------------------------------------------------------------------------------------------------------------------------
2nd Quarter - Total                                      (994)        (418)        (645)        (261)       (.62)       (.25)
----------------------------------------------------------------------------------------------------------------------------


     Restructuring actions announced on April 2 will eliminate 5,500 employee
positions and reduce the contractor work force by 1,300.  Projected annualized
cost savings are expected to exceed $400 million by the end of 2002.  The
company anticipates that about one-third of these savings would be realized by
year-end 2001.

                                       3


Segment Sales
-------------

     Regional segment sales and related variances for the second quarter 2001
compared with the second quarter 2000 are summarized below:



-----------------------------------------------------------------------------------------------------------------
                               Segment Sales                               % Change Due To
-----------------------------------------------------------------------------------------------------------------
                              Q2'01        % Change       Local        Currency                  Pharmaceuticals/
                               $B         vs. Q2 `00      Price         Effect        Volume          Other*
-----------------------------------------------------------------------------------------------------------------
                                                                               
Worldwide                      7.8            (12)          1             (2)          (9)              (2)
-----------------------------------------------------------------------------------------------------------------
   U.S.                        3.9            (16)          1              0          (14)              (3)
-----------------------------------------------------------------------------------------------------------------
   Europe                      1.9             (4)          3             (5)          (2)               0
-----------------------------------------------------------------------------------------------------------------
   Asia Pacific                1.1             (7)          1             (5)          (3)               0
-----------------------------------------------------------------------------------------------------------------
   Canada, Mexico,
      S. America               0.8            (12)         (4)            (2)          (4)              (2)
-----------------------------------------------------------------------------------------------------------------


          *   Includes impact from reduced ownership in DuPont Photomasks. In
              addition, the Pharmaceuticals segment has been isolated for
              purposes of this analysis.

 .  Worldwide volumes declined 9 percent, excluding the lower sales attributable
   to pharmaceuticals and portfolio changes.

 .  U.S. second quarter sales volume (excluding Pharmaceuticals/Other) declined
   14 percent principally reflecting lower volumes in the Specialty Polymers,
   Nylon, Specialty Fibers and Performance Coatings & Polymers segments.

 .  European volume declined 2 percent with local currency prices up 3 percent.
   However, the stronger dollar reduced European sales by 5 percent.

 .  Asia Pacific sales continue to weaken, down 7 percent, reflecting lower
   volume and the negative impact of weaker currencies, particularly the
   Japanese yen.

Business Segment Performance
----------------------------

     The following compares second quarter 2001 results before one-time items
for each segment with those for the second quarter 2000, reflecting the segment
realignments described in note(a) to the Consolidated Segment Information
accompanying this news release.

 .  Performance Coatings & Polymers - Sales were 12 percent lower than 2000
   reflecting lower worldwide vehicle builds and lower refinish sales, as well
   as the weak euro. Increased raw material costs were a significant factor in
   lower results in Engineering Polymers and Elastomers, in addition to lower
   volumes. Segment ATOI declined 59 percent.

                                       4


 .  Specialty Fibers - Sales and ATOI were 11 percent and 46 percent lower,
   respectively. Continued earnings growth from Advanced Fiber Systems was more
   than offset by lower earnings from Apparel and Textile Sciences which
   declined 85 percent, adversely affected by the weak euro, higher raw material
   costs, and very weak U.S. apparel and textile markets. Earnings for Nonwovens
   were essentially flat on modestly higher sales.

 .  Specialty Polymers - Sales were down 12 percent. Segment ATOI declined 54
   percent with lower earnings in all strategic business units. Electronic
   Technologies and Fluoropolymers were adversely affected by the significant
   slowdown in electronics and related high-technology markets. The decline in
   Packaging & Industrial Polymers earnings resulted from lower volumes and
   higher raw materials costs. DuPont Surfaces and Imaging Technologies results
   also reflect the economic downturn.

 .  Pigments & Chemicals - ATOI declined 34 percent on 8 percent lower sales with
   lower earnings in all strategic business units reflecting 7 percent lower
   worldwide volume. Segment earnings were also negatively affected by higher
   raw material and energy costs in White Pigment & Mineral Products and DuPont
   Chemical Solutions Enterprise.

 .  Polyester - Sales were 11 percent lower, reflecting depressed conditions in
   worldwide markets. Margins continue to be reduced by higher raw material and
   energy costs. The second quarter loss was $17 million.

 .  Nylon - Sales decreased 12 percent with ATOI down 97 percent, principally
   reflecting the impact of 23 percent lower U.S. volumes and higher raw
   material costs. Sales declines were principally due to lower flooring
   volumes, particularly in the United States.

 .  Agriculture & Nutrition - ATOI declined 26 percent on 8 percent lower sales.
   Pioneer sales were $771 million, down 4 percent, while remaining sales in the
   segment were down 12 percent. Crop Protection earnings were principally
   affected by lower U.S. volumes and by currency in Europe and Asia.

 .  Pharmaceuticals - ATOI was $10 million versus $51 million last year,
   primarily due to 23 percent lower sales. The DuPont share of
   Cozaar(R)/Hyzaar(R) U.S. operating profits increased this quarter versus last
   year. Major product sales are shown below:



          ---------------------------------------------------------------------------------------------
               ($ in millions)                                   2Q 2001         1Q 2001        2Q 2000
          ---------------------------------------------------------------------------------------------
                                                                                        
          Coumadin(R)                                                 52             26              69
          ---------------------------------------------------------------------------------------------
          Sustiva(TM)                                                 87             55             141
          ---------------------------------------------------------------------------------------------
          Cardiolite(R)/Miraluma(TM)                                  53             18              62
          ---------------------------------------------------------------------------------------------


Outlook
-------
     The company maintains a cautious view of the broader business environment
in the second half of 2001, characterized by the following key elements:

 .  It does not appear that the second quarter marked the bottom of the current
   economic downturn, and we expect conditions to continue to deteriorate into
   the third quarter.

                                       5


 .  We expect the U.S. economy to stabilize, but not to materially improve, by
   the fourth quarter this year. We believe that any modest upturn in the U.S.
   is likely to be offset by further declines in Europe, Asia, and South
   America. We also expect the electronics markets to continue to decline
   through the fourth quarter of 2001.

 .  Although we are hopeful that the burgeoning financial crisis in Argentina and
   Brazil will not spread, we do expect it to affect fourth quarter southern
   hemisphere agricultural sales and our other businesses in the region.

 .  For the second half of 2001, the company expects the purchased costs for raw
   materials to remain at approximately current levels and the U.S. dollar to
   stay in roughly its current exchange range versus trade weighted average
   currencies.

     Based on this view, the company anticipates that the third quarter 2001
will be substantially more challenging than the second quarter, as judged by
year-over-year earnings per share (EPS) comparisons.  Accordingly, the company
expects earnings comparisons in the third quarter to show a sequential decline
at least as great as that seen in the second quarter.  The company does expect
some mitigation of these downward trends in the fourth quarter of 2001, due to
savings from its restructuring activities and assuming stabilization in the U.S.
manufacturing sector.

     "We cannot control the economy, but we can control how we operate," said
Holliday.  "In today's economy that means accelerating cost savings from
restructuring, strictly limiting discretionary spending, reducing capital
expenditures and intensely focusing on stimulating sales into global markets."

Forward-Looking Statements:  This news release contains forward-looking
statements based on management's current expectations, estimates and
projections.  All statements that address expectations or projections about the
future, including statements about the company's strategy for growth, product
development, market position, expected expenditures and financial results are
forward-looking statements.  Some of the forward-looking statements may be
identified by words like "expects," "anticipates," "plans," "intends,"
"projects," "indicates," and similar expressions.  These statements are not
guarantees of future performance and involve a number of risks, uncertainties
and assumptions.  Many factors, including those discussed more fully elsewhere
in this release and in documents filed with the Securities and Exchange
Commission by DuPont, particularly its latest annual report on Form 10-K and
quarterly report on Form 10-Q, as well as others, could cause results to differ
materially from those stated.  These factors include, but are not limited to
changes in the laws, regulations, policies and economic conditions, including
inflation, interest and foreign currency exchange rates, of countries in which
the company does business; competitive pressures; successful integration of
structural changes, including restructuring plans, acquisitions, divestitures
and alliances; cost of raw materials, research and development of new products,
including regulatory approval and market acceptance; and seasonality of sales of
agricultural products.


                                     # # #
7/25/01

                                       6


E. I. DU PONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES



                                                                       Three Months Ended                  Six Months Ended
CONSOLIDATED INCOME STATEMENT                                               June 30                            June 30
                                                                 ------------------------------    ------------------------------
(Dollars in millions, except per share)                              2001              2000             2001             2000
                                                                 ------------       -----------    -------------     ------------
                                                                                                         
SALES                                                                  $6,997            $7,914          $13,856          $15,507
Other Income(a)                                                           216               218              386              566
                                                                 ------------       -----------    -------------     ------------

     Total                                                              7,213             8,132           14,242           16,073
                                                                 ------------       -----------    -------------     ------------

Cost of Goods Sold and Other Expenses(b)                                4,615             5,028            9,101            9,884
Selling, General and Administrative Expenses                              825               809            1,582            1,566
Depreciation                                                              340               353              667              704
Amortization of Goodwill and Other Intangible Assets                      113               109              225              216
Research and Development Expense                                          437               460              847              881
Interest and Debt Expense                                                 166               210              344              411
Purchased In-Process Research and Development(c)                            -                 -                -              (11)
Employee Separation Costs and Write-Down of Assets(d)                   1,046                98            1,046               98
                                                                 ------------       -----------    -------------     ------------

     Total                                                              7,542             7,067           13,812           13,749
                                                                 ------------       -----------    -------------     ------------

INCOME (LOSS) BEFORE INCOME TAXES AND
     MINORITY INTERESTS                                                  (329)            1,065              430            2,324
Provision for Income Taxes                                               (139)              355              133              794
Minority Interests in Earnings of Consolidated Subsidiaries                23                22               26               39
                                                                 ------------       -----------    -------------     ------------

INCOME (LOSS) BEFORE CUMULATIVE EFFECT OF A
   CHANGE IN ACCOUNTING PRINCIPLE                                        (213)              688              271            1,491
Cumulative Effect of a Change in Accounting Principle,
     Net of Income Taxes(e)                                                 -                 -               11                -
                                                                 ------------       -----------    -------------     ------------

NET INCOME (LOSS)                                                      $ (213)           $  688          $   282          $ 1,491
                                                                 ============       ===========    =============     ============

---------------------------------------------------------------------------------------------------------------------------------

BASIC EARNINGS (LOSS) PER SHARE OF COMMON STOCK(f)(g)
     Income (Loss) before Cumulative Effect of a Change in
        Accounting Principle                                           $ (.21)           $  .66          $   .26          $  1.42
     Cumulative Effect of a Change in Accounting Principle                  -                 -              .01                -
                                                                 ------------       -----------    -------------     ------------

     Net Income (Loss)                                                 $ (.21)           $  .66          $   .27          $  1.42
                                                                 ============       ===========    =============     ============

DILUTED EARNINGS (LOSS) PER SHARE OF COMMON STOCK(f)
     Income (Loss) before Cumulative Effect of a Change in
        Accounting Principle                                           $ (.21)           $  .65          $   .25          $  1.41
     Cumulative Effect of a Change in Accounting Principle                  -                 -              .01                -
                                                                 ------------       -----------    -------------     ------------

     Net Income (Loss)                                                 $ (.21)           $  .65          $   .26          $  1.41
                                                                 ============       ===========    =============     ============

DIVIDENDS PER SHARE OF COMMON STOCK                                    $  .35            $  .35          $   .70          $   .70
                                                                 ============       ===========    =============     ============


                                       7


FOOTNOTES TO CONSOLIDATED INCOME STATEMENT
------------------------------------------


(a)  Second quarter 2001 includes a $52 gain resulting from the Company's sale
     of stock that reduced its ownership interest in DuPont Photomasks.  Year-
     to-date 2000 includes a $176 gain resulting from the sale of certain equity
     securities classified as available for sale.

(b)  In accordance with purchase accounting rules applied to the acquisition of
     the remaining 80 percent ownership interest in Pioneer on October 1, 1999,
     Pioneer inventory was increased to fair value.  This inventory step-up
     generated noncash charges to cost of goods sold as the inventory on hand at
     the acquisition date was sold.  Year-to-date 2001 charges were $133.
     Second quarter and year-to-date 2000 charges were $220 and $567,
     respectively.

     During second quarter 2000, a charge of $100 was also recorded to increase
     the Company's reserve for "Benlate" 50 DF fungicide litigation.

(c)  Purchased in-process research and development represents the value assigned
     in a purchase business combination to research and development projects of
     the acquired business that were commenced but not yet completed at the date
     of acquisition, for which technological feasibility has not yet been
     established, and which have no alternative future use in research and
     development activities or otherwise.  Year-to-date 2000 includes a credit
     of $11 that was recorded based on revisions of preliminary purchase price
     allocations associated with the Pioneer acquisition.

(d)  Second quarter 2001 charges of $1,046 include $441 associated with
     separation costs for approximately 5,500 employees, $303 for asset
     impairments (principally the write-down of polyester assets to be sold to
     Alpek), and $302 related to the shutdown and dismantlement of several
     facilities.

     Second quarter 2000 charges of $98 result from the continued restructuring
     of the performance coatings businesses.  This includes charges of $73
     attributable to employee separation costs for about 1,000 employees,   $13
     for the shutdown of related manufacturing facilities, and $12 for other
     exit costs.

(e)  On January 1, 2001, the company adopted SFAS No. 133, "Accounting for
     Derivative Instruments and Hedging Activities," as amended.

(f)  Earnings per share are calculated on the basis of the following average
     number of common shares outstanding:



                         Three Months Ended                 Six Months Ended
                              June 30                           June 30
                 -------------------------------  ------------------------------
                   Basic            Diluted         Basic             Diluted
                 -------------  ----------------  ------------    --------------
                                                      
          2001   1,041,759,701     1,041,759,701  1,041,962,856    1,047,878,439
          2000   1,045,857,572     1,053,658,428  1,046,447,044    1,055,367,888


(g)  Year-to-date earnings per share do not equal the sum of quarterly earnings
     per share due to changes in average share calculations.

                                       8


E. I. DUPONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES



                                                                       Three Months Ended                  Six Months Ended
CONSOLIDATED SEGMENT INFORMATION(a)                                          June 30                            June 30
                                                                  ------------------------------      -----------------------------
(Dollars in millions)                                                 2001              2000              2001             2000
                                                                  ------------       -----------      ------------     ------------
                                                                                                           
SEGMENT SALES(b)
-------------
Agriculture & Nutrition                                                 $1,517            $1,650           $ 3,055          $ 3,199
Nylon                                                                      708               804             1,382            1,553
Performance Coatings & Polymers                                          1,514             1,716             2,972            3,369
Pharmaceuticals                                                            304               394               509              783
Pigments & Chemicals                                                       952             1,038             1,903            1,998
Polyester                                                                  543               613             1,046            1,129
Specialty Fibers                                                         1,141             1,284             2,327            2,600
Specialty Polymers                                                       1,009             1,151             2,048            2,242
Other                                                                       81               143               162              266
                                                                  ------------       -----------      ------------     ------------

     Total Segment Sales                                                 7,769             8,793            15,404           17,139

Elimination of Intersegment Transfers                                     (127)             (177)             (273)            (336)
Elimination of Equity Affiliate Sales                                     (654)             (703)           (1,282)          (1,298)
Miscellaneous                                                                9                 1                 7                2
                                                                  ------------       -----------      ------------     ------------

     CONSOLIDATED SALES                                                 $6,997            $7,914           $13,856          $15,507
                                                                  ------------       -----------      ------------     ------------

AFTER-TAX OPERATING INCOME (LOSS)(c)
---------------------------------
Agriculture & Nutrition(d)                                              $  126            $   78           $   292          $   216
Nylon                                                                     (141)               74              (124)             141
Performance Coatings & Polymers(e)                                          17               129               149              308
Pharmaceuticals                                                             10                51               (54)             105
Pigments & Chemicals                                                        93               186               217              350
Polyester                                                                 (281)                8              (289)              12
Specialty Fibers                                                            74               191               225              418
Specialty Polymers                                                          53               183               183              348
Other(f)                                                                    (7)                6                (4)               6
                                                                  ------------       -----------      ------------     ------------

     Total Segment ATOI                                                    (56)              906               595            1,904

Interest & Exchange Gains and Losses                                       (88)             (136)             (185)            (259)
Corporate Expenses                                                         (69)              (82)             (139)            (154)
                                                                  ------------       -----------      ------------     ------------

     INCOME (LOSS) FROM OPERATIONS                                      $ (213)           $  688           $   271          $ 1,491
                                                                  ============       ===========      ============     ============


                                       9


FOOTNOTES TO CONSOLIDATED SEGMENT INFORMATION
---------------------------------------------

(a) Certain reclassifications of segment data have been made to reflect changes
    in organizational structure. The Agriculture & Nutrition segment now
    includes the Pioneer business. The Specialty Fibers segment now includes the
    new Apparel & Textile Sciences SBU, which comprises the former Lycra(R)
    business, nylon apparel and specialty textile businesses, and the polyester
    branded specialties businesses.

(b) Includes pro rata share of equity affiliate sales and intersegment
    transfers. Excludes sales of intermediates by DuPont to joint ventures
    within the Nylon and Polyester segments.

(c) Second quarter 2001 charges of $679 result from employee terminations,
    facility shutdowns, and asset impairments in the following segments:
    Agriculture & Nutrition - $80; Nylon - $143; Performance Coatings &
    Polymers -$60; Pigments & Chemicals - $30; Polyester - $264; Specialty
    Fibers - $30; Specialty Polymers - $32; and Other - $40.

(d) Second quarter 2000 includes a charge of $138 resulting from the sale of
    acquired Pioneer inventories which, in accordance with purchase accounting
    rules, were recorded at fair value on October 1, 1999 and a charge of $62 to
    increase the Company's reserve for "Benlate" 50 DF fungicide litigation.
    Year-to-date 2001 and 2000 include noncash charges of $83 and $353,
    respectively, resulting from the sale of acquired Pioneer inventories.
    Year-to-date 2000 also includes the $62 charge for "Benlate" litigation
    discussed above, a $109 gain resulting from the sale of certain equity
    securities classified as available for sale, and a credit of $11 to reduce
    the preliminary purchase price allocated to acquired in-process research and
    development.

(e) Second quarter 2000 includes a charge of $61 related to employee separation
    costs for about 1,000 employees, the shutdown of related manufacturing
    facilities, and other exit costs.

(f) Second quarter 2001 includes a gain of $34 resulting from the Company's sale
    of stock that reduced its ownership interest in DuPont Photomasks.

                                       10


E. I. DUPONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES


SEGMENT SALES(a)
(2nd QUARTER 2001 VS. 2nd QUARTER 2000)




                                                  Segment Sales
                                               Three Months Ended                Percentage Change Due to:
                                                    June 30                      -------------------------
                                           ------------------------------        U.S. $
                                                 $             % Change          Price           Volume             Other(b)
                                           -----------     --------------      ---------      ------------      --------------
                                                                                                 
Agriculture & Nutrition                         $1,517            (8)             (3)               (5)
Nylon                                              708           (12)              1               (13)
Performance Coatings & Polymers                  1,514           (12)             (1)              (11)
Pharmaceuticals                                    304           (23)              0               (23)
Pigments & Chemicals                               952            (8)             (1)               (7)
Polyester                                          543           (11)              1               (12)
Specialty Fibers                                 1,141           (11)             (3)               (8)
Specialty Polymers                               1,009           (12)              0               (12)
Other                                               81           (43)              0                 0                   (43)
                                           -----------

     Total                                      $7,769           (12)             (2)               (9)                   (1)
                                           ===========

___________________________
(a)  Includes intersegment transfers and pro rata share of equity affiliate
     sales.
(b)  Reflects reduced interest in DuPont Photomasks, Inc.








SEGMENT INFORMATION                                    Three Months Ended                           Six Months Ended
EXCLUDING IMPACT OF ONE-TIME ITEMS -                        June 30                                      June 30
                                                   -----------------------------------     ---------------------------------
 (Dollars in millions)                                2001      2000        % Chg.            2001       2000       % Chg.
                                                   ---------  ---------   ----------       ---------   --------   -----------
                                                                                                
AFTER-TAX OPERATING INCOME (LOSS)
Agriculture & Nutrition                              $ 206      $  278       (26)            $  455      $  511       (11)
Nylon                                                    2          74       (97)                19         141       (87)
Performance Coatings & Polymers                         77         190       (59)               209         369       (43)
Pharmaceuticals                                         10          51       (80)               (54)        105       N/M
Pigments & Chemicals                                   123         186       (34)               247         350       (29)
Polyester                                              (17)          8       N/M                (25)         12       N/M
Specialty Fibers                                       104         191       (46)               255         418       (39)
Specialty Polymers                                      85         183       (54)               215         348       (38)
Other                                                   (1)          6       N/M                  2           6       (67)
                                                   -------    --------                     --------    --------

     Total Segment ATOI                                589       1,167       (50)             1,323       2,260       (41)

Interest & Exchange Gains (Loss)                       (88)       (136)                        (185)       (259)
Corporate Expenses                                     (69)        (82)                        (139)       (154)
                                                   -------    --------                     --------    --------

     INCOME FROM OPERATIONS                          $ 432      $  949       (54)            $  999      $1,847       (46)
                                                   =======    ========                     ========    ========


                                       11


E. I. DUPONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES


FINANCIAL SUMMARY
-----------------
(Dollars in millions, except per share)



                                                         Three Months Ended                                Six Months Ended
                                                               June 30                                           June 30
                                             --------------------------------------------   --------------------------------------
                                                 2001            2000         % Chg.             2001            2000      % Chg.
                                             -----------     -----------     ------------   ------------     ------------  -------
                                                                                                         
Selected Income Statement Data -

Excluding Impact of One-Time Items
And Cumulative Effect of a Change
In Accounting Principle
Consolidated Sales                             $6,997           $7,914          (12)%          $13,856         $15,507       (11)%
Segment Sales                                   7,769            8,793          (12)            15,404          17,139       (10)
Segment ATOI                                      589            1,167          (50)             1,323           2,260       (41)
EBIT                                              846            1,709          (51)             1,932           3,345       (42)
EBITDA                                          1,299            2,171          (40)             2,824           4,265       (34)
Income from Operations                            432              949          (54)               999           1,847       (46)
EPS - Diluted                                    0.41             0.90          (54)              0.95            1.75       (46)




                                      2nd Quarter 2001 Vs.
                                      2nd Quarter 2000
                                      ----------------


Segment ATOI Variance Analysis -
Excluding Impact of One-Time Items
----------------------------------

Local Prices                                         $  35
Volume                                                (270)
Costs                                                 (315)
Currency                                               (35)
Other                                                    7
                                                     -----

   Total                                             $(578)
                                                     =====


Six Sigma Estimated Annualized Benefits - $ Pretax
--------------------------------------------------

From Ongoing Projects                                $ 600
From Completed Projects                              $ 650



                                       12


                                   SIGNATURE



     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                   E. I. DUPONT DE NEMOURS AND COMPANY
                                                (Registrant)



                                                  /s/ D. B. Smith
                                   -----------------------------------------
                                                   D. B. Smith
                                               Assistant Controller


July 25, 2001

                                      13